Best in Biotech 22 Jul 2025 Seven biotechs in Belgium making leaps in the clinic Meet the most successful biotech companies in Belgium, a country that makes a huge contribution to the biotech industry. July 22, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 2 Feb 2024BioSenic showcasing knee osteoarthritis treatment Explore a groundbreaking approach to knee osteoarthritis treatment with BioSenic’s JTA-004. Listen to our podcast to learn more! February 2, 2024 Share WhatsApp Twitter Linkedin Email
Best in Biotech 3 Jan 2024 The top-performing countries in biotechnology (according to the OECD) Explore the OECD’s top-performing countries for biotech, from the U.S. powerhouse to the promising landscapes of the U.K., Belgium, and more. January 3, 2024 - 14 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2023 Mithra announces positive data from CSF-1R inhibitor program Mithra, a company dedicated to women’s health, has announced new positive data from preclinical studies on inhibitors of CSF-1R in development, in collaboration with BCI Pharma, for the treatment of endometriosis, oncology and inflammatory disorders. Colony-stimulating factor 1 receptor (CSF-1R) is a cell-surface tyrosine kinase receptor and a key regulator of macrophage biology and homeostasis. […] June 15, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2023 New therapy for prevention and treatment of COVID-19 ExeVir Bio, and its scientific founders at Belgium’s VIB, Flanders’ leading life sciences institute, have published a pre-print paper by De Cae et al., entitled “Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane-proximal epitope of the spike.” Nearly all SARS-CoV-2 neutralizing antibodies used in the clinic show substantial loss of potency against the […] March 13, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Mar 2023 Lilly to develop Confo pain drug Confo Therapeutics, which works on the discovery of medicines targeting G-protein coupled receptors (GPCRs), has announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and back-up compounds. CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R) is currently in phase 1 clinical development. It represents a […] March 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jan 2023 Vésale Bioscience receives €1.8M grant for AMR phage project Belgian company Vésale Bioscience has received €1.8 million ($1.9 million) in grants from the European Innovation Council (EIC) Accelerator Fund for its PhageDiag project, a phagogram using artificial intelligence that enables decentralized diagnostics and personalized treatment. According to the World Health Organization (WHO), antimicrobial resistance (AMR) is one of the top 10 global public health […] January 18, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 ExeVir Bio secures funding for COVID program ExeVir Bio, a Belgian biotech company developing nanobody therapies for broad protection against infectious diseases, has secured a venture debt financing agreement of up to €25 million ($26.5 million) with the European Investment Bank (EIB). The EIB financing will help advance ExeVir Bio’s lead asset, XVR012, into clinical trials for COVID-19. ExeVir Bio’s COVID-19 development […] January 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 PDC*line Pharma presents first immunological results from trial with PDC*lung01 PDC*line Pharma, a clinical stage biotech company has announced the first immunological results of its PDC-LUNG-101 phase 1/2 clinical trial investigating PDC*Lung01. The company’s lead therapeutic is the off-the-shelf cancer vaccine candidate for non-small cell lung cancer (NSCLC). PDC*line Pharma develops potent and scalable active immunotherapies for cancers. The preliminary data was presented today at […] December 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 Novadip bone healing trial yields positive results Novadip Biosciences SA has announced positive data from its phase 1/2 clinical trial evaluating the safety and clinical activity of its investigational product, NVD-003. The study was on patients with severe bone non-union (BNU) of the lower limb following trauma. Novadip is a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to […] December 8, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 Polyplus announces completion of acquisition of Xpress Biologics to expand plasmid DNA Polyplus has announced the completion of an acquisition of Belgian Xpress Biologics to expand plasmid DNA technology. Xpress Biologics specializes in the production of plasmid DNA and protein using microbial expression systems. Polypus concentrates on the manufacturing of advanced therapeutic medicinal products from research to commercial grade. The acquisition will strategically expand the Polyplus plasmid […] December 8, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 UCB publishes Lennox-Gastaut syndrome study data UCB has announced the publication of long-term open-label extension (OLE) study results of FINTEPLA (fenfluramine) CIV in the journal Epilepsia. Long-term efficacy and safety findings showed that FINTEPLA, when added to a patient’s current anti-epileptic treatment regimen for seizures associated with Lennox-Gastaut syndrome (LGS), was effective in reducing the frequency of multiple seizure types and […] November 23, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email